XASX
SLX
Market cap821mUSD
Oct 09, Last price
4.01AUD
1D
-5.42%
1Q
-29.65%
Jan 2017
915.19%
Name
Silex Systems Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Silex Systems Limited, a technology commercialization company, engages in the research and development, commercialization, and license of SILEX laser enrichment technology in Australia, the United States, and the United Kingdom. It operates through three segments: Silex Systems, Translucent, and Silex USA. The company also sells its cREO technology. In addition, it develops its laser-based enrichment technology for use in various applications comprising uranium production and enrichment for nuclear power; silicon enrichment for silicon quantum computing; and medical isotope enrichment for new cancer therapies. Silex Systems Limited was incorporated in 1987 and is based in Lucas Heights, Australia.
Related entities
Subsidiaries
Translucent, Inc
Key people
Craig Andrew Roy
Non-Executive Chairman of the Board · since 2019
Michael P. Goldsworthy
Chief Executive Officer, Managing Director, Executive Director
Julie E. Ducie
Chief Financial Officer, Company Secretary · since 2012
Non-Executive Director · since 2007
Independent Non-Executive Independent Director · since 2019
Legal address
64 New Illawarra Road
LUCAS HEIGHTS, NSW 2234
AU
LUCAS HEIGHTS, NSW 2234
AU
Headquarters
Lucas Heights Science & Technology, Centre Build'
64 New Illawarra Road
LUCAS HEIGHTS, NSW 2234
AU
64 New Illawarra Road
LUCAS HEIGHTS, NSW 2234
AU
Previous name
SILEX SYSTEMS PTY LIMITED
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||